Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

Germain Vincent; Scherlinger Marc; Barnetche Thomas; Schaeverbeke Thierry

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

【24h】

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

机译：从发芽素intiximab切换到其生物仿制性CT-P13：NOCEBO效应的重量后长期随访

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2020年第1期|共2页
作者
Germain Vincent; Scherlinger Marc; Barnetche Thomas; Schaeverbeke Thierry;
展开▼
作者单位

CHU Bordeaux Serv Rhumatol Dept Rheumatol Bordeaux France;

CHU Bordeaux Serv Rhumatol Dept Rheumatol Bordeaux France;

CHU Bordeaux Serv Rhumatol Dept Rheumatol Bordeaux France;

CHU Bordeaux Serv Rhumatol Dept Rheumatol Bordeaux France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect [J] . Germain Vincent, Scherlinger Marc, Barnetche Thomas, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2020,第1期

机译：从发芽素intiximab切换到其生物仿制性CT-P13：NOCEBO效应的重量后长期随访
2. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial [J] . Jorgensen Kristin K., Olsen Inge C., Goll Guro L., The Lancet . 2017,第10086期

机译：与发芽治疗的发起者英美昔单抗切换到生物仿制物CT-P13与发起者英夫利昔单抗（NOR-SWITCH）的治疗相比：52周，随机，双盲，非劣势试验
3. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial (vol 389, pg 2304, 2017) [J] . Jorgensen K. K., Olsen I. C., Goll G. L. The Lancet . 2017,第10086期

机译：从发起者infliximab转换为生物仿制物CT-P13与发起者incriximab（NOR-SWITCH）的维护治疗相比：52周，随机，双盲，非劣势试验（Vol 389，PG 2304,2017）
4. INNOVATOR AND BIOSIMILAR INFLIXIMAB: COMPARABILITY ASSESSMENT OF THE HOST CELL PROTEINS AND PROTEIN HIGHER ORDER STRUCTURE [C] . Jing Fang, Catalin Doneanu, William R. Alley, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：创新者和生物纤维单纤维生素：宿主细胞蛋白和蛋白质高阶结构的可比性评估
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Extended report: Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study [O] . Dae Hyun Yoo, Nenad Prodanovic, Janusz Jaworski, -1

机译：扩展报告：类风湿关节炎患者中CT-P13（生物仿制药英夫利昔单抗）的疗效和安全性：在PLANETRA扩展研究中从参考英夫利昔单抗转换为CT-P13与持续进行CT-P13之间的比较
7. POS0592 BIOSIMILAR INFLIXIMAB THERAPY IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS: A LONG-TERM FOLLOW-UP STUDY ON INFLIXIMAB-NAÏVE PATIENTS AND PATIENTS SWITCHED FROM THE ORIGINATOR TO THE BIOSIMILAR CT-P13 [O] . B. Fautrel, M. Assing, N. Mammar, 2021

机译：POS0592 BioSimilar Infliximab疗法在类风湿性关节炎，强直性脊柱炎和银屑病关节炎：对富生素-Naïve患者的长期随访研究和从发起者转换为生物邮件CT-P13的患者

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect

著录项

相似文献

相关主题

期刊订阅